ANIP

In the past six months, ANI Pharmaceuticals' stock has been impacted by several key events. The company reported Q3 2025 earnings per share (EPS) of $2.04, surpassing estimates, with quarterly revenue also exceeding expectations. In Q1 2026, ANI Pharmaceuticals delivered a robust financial performance, significantly exceeding market expectations, with the stock rising by 4.81% in premarket trading. Concurrent with its Q1 2026 earnings, ANI Pharmaceuticals raised its full-year 2026 financial guidance. Effective May 8, 2026, ANI's board of directors authorized a new 3-year share repurchase program to buy back up to $100 million in common stock. In May 2026, Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" to a "strong-buy" rating. Over the past 52 weeks, ANIP's stock has traded between a low of $56.71 and a high of $99.50.